Immunology Seminar

December 3^rd at 14-15 (Finland time)

Virtual event

Flyer

Olli Dufva, Wellcome Sanger Insitute, Cambridge Stem Cell Institute, University of Cambridge, United Kingdom: Single-cell functional genomics of natural killer cell evasion in cancer

Register for the Immunology Seminar Series email list to get calendar invitation to the online seminar: https://link.webropolsurveys.com/S/D29C32AA6E8A2F7A

Host: Professor Riitta Lahesmaa ( rilahes@utu.fi )

Immunology seminar series is jointly organised by the Finnish Society for Immunology, InFLAMES Flagship and Turku Bioscience. For further information contact Anne Lahdenperä  ( ankahy@utu.fi ) or Riitta Lahesmaa ( rilahes@utu.fi ), University of Turku.

****

Olli Dufva is a physician-scientist and a postdoctoral fellow at the Wellcome Sanger Institute and University of Cambridge in the laboratories of Prof Sarah Teichmann and Dr Mathew Garnett. His research focuses on deciphering genomic determinants of anti-cancer immunity and developing improved cellular immunotherapies using single-cell genomics, organoid models and genetic engineering. Olli completed his medical degree and his PhD at the University of Helsinki, where he studied immune interactions and precision medicine in blood cancers with Prof Satu Mustjoki. This year Olli Dufva was awarded the ACTERIA Doctoral Thesis Prize in Immunology for his work on “Functional Immunogenomics in Hematological Malignancies”.

Olli’s work at the intersection of immunology and cancer has included mapping the immunogenomic landscape of blood cancers by integrating transcriptomic and multi-omic data across thousands of patient samples and applying high-throughput drug screens, CRISPR screens, and single-cell analysis to lymphocyte – cancer cell co-cultures to find immunotherapy-enhancing drugs and genetic resistance mechanisms.

Selected publications:

Dufva O, Gandolfi S, …, Mitsiades CS, Mustjoki S. Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers. Immunity. 2023 doi: 10.1016/j.immuni.2023.11.008

Dufva O, Pölönen P, …, Heinäniemi M, Mustjoki S. Immunogenomic Landscape of Hematological Malignancies. Cancer Cell. 2020 doi: 10.1016/j.ccell.2020.06.002

Dufva O, Koski J, Maliniemi P,  …, Keränen MAI, Korhonen M, Mustjoki S. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood. 2020 doi: 10.1182/blood.2019002121